Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease - Janelidze, Shorena; Stomrud, Erik; Smith, Ruben; Palmqvist, Sebastian; Mattsson, Niklas; Airey, David C.; Proctor, Nicholas K.; Chai, Xiyun; Shcherbinin, Sergey; Sims, John R.; Triana-Baltzer, Gallen; Theunis, Clara; et al. (Nature communications, 2020)
Keywords: 692/53/2421; 692/617/375/132/1283; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer's disease; Basic Medicine; Biomarkers; Biomarkers - cerebrospinal fluid; Brain; Brain - diagnostic imaging; Carbolines - administration & dosage; Cerebrospinal fluid; Contrast Media - administration & dosage; Dementia disorders; Diagnosis, Differential; Diagnostic systems; Feasibility Studies; Female; Fluorine isotopes; Humanities and Social Sciences; Humans; Immunoassay; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicinska och farmaceutiska grundvetenskaper; Metabolism; Middle Aged; multidisciplinary; Neocortex; Neurodegenerative diseases; Neurosciences; Neurovetenskaper; Phosphorylation; Positron emission; Positron emission tomography; Science; Science (multidisciplinary); Sweden; Tau protein; tau Proteins - cerebrospinal fluid; tau Proteins - metabolism; Threonine; Tomography; Sweden